Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
13,303 total articles
Rocket Lab Corporation has been awarded a $90 million contract by the U.S. Space Force's Space Systems Command to design, build, and operate two geostationary satellites equipped with Heimdall space domain awareness payloads. This marks Rocket Lab's entry into satellite production for geostationary orbit, extending its vertically integrated mission…
HUTCHMED announced that new and updated clinical data from several of its drug candidates, including savolitinib and fruquintinib, will be presented at the ASCO Annual Meeting 2026. Key highlights include positive Phase II results for savolitinib in MET-amplified gastric cancer with the primary endpoint met and priority review in China. Additional …
Ascentage Pharma announced clinical data from six abstracts presented at ASCO 2026 showcasing efficacy and safety results for its key drug candidates targeting various cancers including chronic myeloid leukemia and pediatric solid tumors. Ongoing Phase III trials for olverembatinib and lisaftoclax further support the company's growth potential in o…
Fennec Pharmaceuticals announced new independent research findings on PEDMARK®, its FDA-approved treatment to reduce cisplatin-induced ototoxicity, will be presented at the 2026 ASCO Annual Meeting. The studies demonstrate PEDMARK's safety, efficacy, and feasibility for use beyond pediatric populations, including adolescent, young adult, and adult …
Biogen and Denali Therapeutics announced that the Phase 2b LUMA study evaluating BIIB122 (DNL151), a LRRK2 inhibitor, in early-stage idiopathic Parkinson's disease failed to meet its primary and secondary endpoints, showing no slowing of disease progression. Consequently, they will discontinue BIIB122 development for idiopathic Parkinson's disease,…
Perspective Therapeutics, Inc. announced that it will present updated data from all three of its clinical programs—[212Pb]VMT-b1-NET for neuroendocrine tumors, [212Pb]VMT01 for melanoma, and [212Pb]PSV359 for solid tumors—at the 2026 ASCO Annual Meeting. The data show continued favorable safety profiles, evidence of tumor response, and no dose-lim…
Zentalis Pharmaceuticals announced encouraging Phase 1b clinical trial results from their MUIR study evaluating the investigational WEE1 inhibitor azenosertib combined with paclitaxel in platinum-resistant ovarian cancer patients. The combination showed a manageable safety profile and promising anti-tumor activity, notably a 39% overall response ra…
Crescent Biopharma announced the presentation of a trial in progress poster for their ASCEND Phase 1/2 global clinical trial of CR-001, a PD-1 x VEGF bispecific antibody targeting multiple solid tumors including NSCLC, gastrointestinal and gynecological cancers. Enrollment is ongoing worldwide, with initial clinical data expected starting Q1 2027. …
Peace Acquisition Corp has priced its initial public offering of 6 million units at $10 per unit valuing the IPO at $60 million. The units will trade on Nasdaq under the ticker PECEU starting May 22, 2026. The company is a blank check acquisition company aiming to target business combinations primarily in Asia, excluding Mainland China, Hong Kong, …
Pliant Therapeutics announced a poster presentation at the 2026 ASCO Annual Meeting highlighting their Phase 1b FORTIFY trial, which is evaluating PLN-101095, a dual integrin inhibitor, in combination with pembrolizumab for patients with immune checkpoint inhibitor refractory solid tumors. The trial is actively enrolling multiple patient cohorts an…
VCI Global Limited disclosed that NASDAQ notified the company of a delayed filing of its 2025 Form 20-F report. The company had previously filed a Form 12b-25 advising the SEC of the delay due to additional time needed for financial review. VCI Global is submitting a compliance plan to NASDAQ and may receive an extension of up to 180 days to regain…
Aktis Oncology announced first-in-human imaging and dosimetry results for AKY-2519, a novel miniprotein radioconjugate targeting B7-H3 expressing tumors, including metastatic castration-resistant prostate cancer and other solid tumors. Data presented at ASCO 2026 demonstrate robust tumor uptake and limited normal tissue exposure, indicating a favor…
Jupiter Neurosciences announced the closing of a $2 million registered direct offering, issuing over 7 million shares to strengthen its cash position. The capital raise extends the company's cash runway to fund its Phase 2a clinical trial for Parkinson’s disease and supports debt reduction efforts to improve shareholder equity. Additionally, funds …
Black Diamond Therapeutics announced positive Phase 2 clinical trial results of silevertinib, an oral brain-penetrant EGFR inhibitor, in treatment-naïve patients with non-small cell lung cancer (NSCLC) harboring non-classical EGFR mutations. The study demonstrated a median progression-free survival of 15.2 months, a 60% objective response rate, and…
Autolus Therapeutics announced publication and upcoming presentation of clinical data from the FELIX Phase Ib/II trial on their T cell therapy candidate obe-cel at the ASCO 2026 meeting. The data shows a 59% overall response rate and median duration of response of 42.6 months in adult patients with relapsed/refractory B-cell acute lymphoblastic leu…
Equus Total Return, Inc. announced its net asset value (NAV) increased to $1.50 per share as of March 31, 2026, up from $1.19 at the end of 2025. The rise was largely due to a $5 million increase in the value of its holdings in Morgan E&P, Inc., benefiting from higher crude oil prices. Despite a slight decrease in the value of its holdings in Citro…
Eikon Therapeutics, Inc. (Nasdaq: EIKN), a late-stage clinical biopharmaceutical company focused on oncology, announced the availability of six abstracts for presentation at the 2026 American Society of Clinical Oncology Annual Meeting. The presentations will highlight updated clinical data and progress for Eikon's advanced drug candidates, includi…
North American Construction Group Ltd. reported the outcomes of its Annual and Special Meeting held on May 20, 2026. Shareholders elected seven directors, approved KPMG LLP as independent auditors, ratified an Advance Notice Bylaw, and passed a non-binding advisory vote on executive compensation. The company operates in heavy civil construction and…
Moleculin Biotech's pooled cardiac safety data for its lead drug candidate Annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting. The data shows no significant cardiotoxicity even at high cumulative doses, supporting the differentiated safety profile of Annamycin in treating acute myeloid leukemia and soft tissue sarco…
Regeneron announced positive Phase 1/2 LINKER-AL2 trial results for Lynozyfic (linvoseltamab) monotherapy in patients with relapsed or refractory systemic amyloid light chain (AL) amyloidosis. Lynozyfic demonstrated deep and rapid hematologic complete responses in all treated patients at the highest dose, with notable improvements in organ function…
Syndax Pharmaceuticals announced that four abstracts involving its FDA-approved menin inhibitor Revuforj (revumenib) have been accepted for presentation at the ASCO 2026 Annual Meeting. Key highlights include an oral presentation showing favorable outcomes in acute leukemia patients receiving revumenib post-hematopoietic stem cell transplantation a…
Akari Therapeutics announced positive preclinical data demonstrating that their lead antibody drug conjugate (ADC), AKTX-101, synergizes with KRAS inhibitors (including adagrasib) to enhance cytotoxic activity against KRAS-mutated pancreatic cancer models. Unlike traditional ADCs, AKTX-101 uses a novel RNA spliceosome modulating payload (PH1) that …
AerSale Corporation announced that CFO Martin Garmendia will present at the upcoming 2026 Jefferies Aftermarket MRO Virtual Summit and hold investor meetings. The company provides aviation aftermarket services including aircraft and engine sales, leasing, and MRO services. The webcast presentation will be available live and replayed on the company’…
Navient Corporation declared a second quarter 2026 dividend of $0.16 per common share, payable on June 19, 2026, to shareholders of record as of June 5, 2026. The company continues to focus on responsible lending, refinancing options, and financial services through its Earnest business unit.
Cardiff Oncology announced a webcast on June 3, 2026, to discuss updated Phase 2 clinical trial data of Onvansertib, their PLK1 inhibitor drug candidate combined with standard-of-care treatments for first-line RAS-mutated metastatic colorectal cancer. Updated results show dose-dependent improvements in overall response rate and progression-free sur…
